4-O-methylhonokiol inhibits colon tumor growth via p21-mediated suppression of NF-κB activity

Oh, Jiyoung; Ban, Jung Ok; Cho, Min-Chul; Jo, Miran; Jung, Jae Kyung; Ahn, Byeongwoo; Yoon, Do‐Young; Han, Sang Bae; Hong, Jin Tae

doi:10.1016/j.jnutbio.2011.03.013

Cited by 22 publications

(26 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our findings, honokiol and magnolol induce G0/G1 cell cycle arrest via induction of p21 in several cancer cells including prostate cancer cells (Hahm and Singh, 2007;Hsu et al, 2007;Lee et al, 2007;Vaid et al, 2010). We previously found that MH induced cell cycle arrest by induction of p21 in colon cancer cells (Oh et al, 2012). PPARg and NF-kB are also important for the p21-mediated cell cycle arrest of cancer cell growth (Hellin et al, 2000).…”

Section: Figuresupporting

confidence: 88%

“…In addition, we previously found that MH inhibited colon cancer cells through the inactivation of NF-kB (Oh et al, 2012). These data suggest that the ability of MH to enhance PPARg activation and its inhibitory action on the constitutive activation of NF-kB are involved in its inhibitory effect on the growth of prostate cancer cells.…”

Section: Figurementioning

confidence: 66%

“…Moreover, many investigators, using components and crude extracts isolated from the Magnolia family, have shown that p21-mediated cell cycle arrest leads to cell growth inhibition (Hahm and Singh, 2007;Lee et al, 2007;. We recently isolated a bioactive compound, 4-O-methylhonokiol (MH) from M. officinalis, and found it suppressed NF-kB activity in macrophages and colon cancer cells (Oh et al, 2009;2012). The growth inhibitory effects of the bioactive constituents of M. officinalis, obovatol, honokiol and magnolol, are thought to be associated with the inhibitory ability of these compounds on NF-kB activity in cancer cells .…”

Section: Introductionmentioning

confidence: 99%

“…The growth inhibitory effects of the bioactive constituents of M. officinalis, obovatol, honokiol and magnolol, are thought to be associated with the inhibitory ability of these compounds on NF-kB activity in cancer cells . In addition, we recently found that MH-induced inhibition of colon tumour growth was accompanied by a suppression of NF-kB activity (Oh et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity

Lee

Ban

et al. 2013

British J Pharmacology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSEThe effects of 4-O-methylhonokiol (MH), a constituent of Magnolia officinalis, were investigated on human prostate cancer cells and its mechanism of action elucidated. EXPERIMENTAL APPROACHThe anti-cancer effects of MH were examined in prostate cancer and normal cells. The effects were validated in vivo using a mouse xenograft model. KEY RESULTSMH increased the expression of PPARg in prostate PC-3 and LNCap cells. The pull-down assay and molecular docking study indicated that MH directly binds to PPARg. MH also increased transcriptional activity of PPARg but decreased NF-kB activity. MH inhibited the growth of human prostate cancer cells, an effect attenuated by the PPARg antagonist GW9662. MH induced apoptotic cell death and this was related to G0-G1 phase cell cycle arrest. MH increased the expression of the cell cycle regulator p21, and apoptotic proteins, whereas it decreased phosphorylation of Rb and anti-apoptotic proteins. Transfection of PC3 cells with p21 siRNA or a p21 mutant plasmid on the cyclin D1/ cycline-dependent kinase 4 binding site abolished the effects of MH on cell growth, cell viability and related protein expression. In the animal studies, MH inhibited tumour growth, NF-kB activity and expression of anti-apoptotic proteins, whereas it increased the transcriptional activity and expression of PPARg, and the expression of apoptotic proteins and p21 in tumour tissues. CONCLUSIONS AND IMPLICATIONMH inhibits growth of human prostate cancer cells through activation of PPARg, suppression of NF-kB and arrest of the cell cycle. Thus, MH might be a useful tool for treatment of prostate cancer. AbbreviationCDK, cycline-dependent kinase; CNBr, cyanogen bromide; DAPI, 4',6-diamidino-2-phenylindole; GSK-3 b, glycogen synthase kinase 3 b; IAP1, inhibitor of apoptosis 1; iNOS, inducible NOS; MH, 4-O-methylhonokiol

show abstract

Section: Figuresupporting

confidence: 88%

Section: Figurementioning

confidence: 66%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity

Lee

Ban

et al. 2013

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…The present study showed NF-B-dependent regulation of p21 WAF1 regardless of the presence or absence of BARF1. NF-B-dependent p21 WAF1 expression has been reported in human cancers, such as colon cancer (44).…”

Section: Discussionmentioning

confidence: 99%

Epstein-Barr Virus-Encoded BARF1 Promotes Proliferation of Gastric Carcinoma Cells through Regulation of NF-κB

Chang

Kim

Roh

et al. 2013

J Virol

View full text Add to dashboard Cite

Caspase‐driven cancer therapies: Navigating the bridge between lab discoveries and clinical applications

Allani,

Akhilesh,

Tiwari

2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Apoptosis is the cell's natural intrinsic regulatory mechanism of normal cells for programmed cell death, which plays an important role in cancer as a classical mechanism of tumor cell death causing minimal inflammation without causing damage to other cells in the vicinity. Induction of apoptosis by activation of caspases is one of the primary targets for cancer treatment. Over the years, a diverse range of natural, synthetic, and semisynthetic compounds and their derivatives have been investigated for their caspase‐mediated apoptosis‐induced anticancer activities. The review aims to compile the preclinical evidence and highlight the critical mechanistic pathways related to caspase‐induced cell apoptosis in cancer treatment. The focus is placed on the key components of the mechanisms, including their chemical nature, and specific attention is given to phytochemicals derived from natural sources and synthetic and semisynthetic compounds. 180+ compounds from the past two decades with potential as anticancer agents are discussed in this review article. By summarizing the current knowledge and advancements in this field, this review provides a comprehensive overview of potential therapeutic strategies targeting apoptosis in cancer cells. The findings presented herein contribute to the ongoing efforts to combat cancer and stimulate further research into the development of effective and targeted anticancer therapies.

show abstract

4-O-methylhonokiol inhibits colon tumor growth via p21-mediated suppression of NF-κB activity

Cited by 22 publications

References 40 publications

4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity

4‐O‐methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21‐mediated suppression of NF‐κB activity

Epstein-Barr Virus-Encoded BARF1 Promotes Proliferation of Gastric Carcinoma Cells through Regulation of NF-κB

Caspase‐driven cancer therapies: Navigating the bridge between lab discoveries and clinical applications

Contact Info

Product

Resources

About